Fang, Bruno
4 papers on CoChatORCID 0009-0004-7703-2366
Most cited papers
- Verified
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 244
- Verified
Quantitative 68 Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177 Lu-PSMA-617 (VISION Trial)
Kuo, P. H., Morris, M. J., Hesterman, J., Kendi, A. T., Rahbar, K., Wei, X. X., Fang, B., Adra, N., Garje, R., Michalski, J. M., et al. (2024) · Radiology
Radiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and Research
Cited by 119
- Verified
[68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.
Kuo, P., Hesterman, J., Rahbar, K., Kendi, A. T., Wei, X. X., Fang, B., Adra, N., Armstrong, A. J., Garje, R., Michalski, J. M., et al. (2022) · Journal of Clinical Oncology
Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications
Cited by 83
- Verified
Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.
Neal, J. W., Santoro, A., Viteri, S., Ponce Aix, S., Fang, B., Lim, F. L., Gentzler, R. D., Goldschmidt, J. H., Khrizman, P., Massarelli, E., et al. (2022) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 18
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free